Dianthus Therapeutics
Biotechnology, 4464 Markham Street, City, New York, 95834, United States, 11-50 Employees
Who is DIANTHUS THERAPEUTICS
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Bas...
Read More
-
Headquarters: 4464 Markham Street, New York City, New York, 95834, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Marino Garcia
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from DIANTHUS THERAPEUTICS
Dianthus Therapeutics Org Chart and Mapping
Similar Companies to Dianthus Therapeutics
Beam Therapeutics
-
501-1000
-
$ 50 Million to 100 Million
Edgewise Therapeutics
-
51-200
-
$ 25 Million to 50 Million
Regulus Therapeutics
-
11-50
-
$ 1 Billion and Over
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Dianthus Therapeutics
Answer: Dianthus Therapeutics's headquarters are located at 4464 Markham Street, City, New York, 95834, United States
Answer: Dianthus Therapeutics's official website is https://dianthustx.com
Answer: Dianthus Therapeutics's revenue is $5 Million to $10 Million
Answer: Dianthus Therapeutics's SIC: 2836
Answer: Dianthus Therapeutics's NAICS: 325414
Answer: Dianthus Therapeutics has 11-50 employees
Answer: Dianthus Therapeutics is in Biotechnology
Answer: Dianthus Therapeutics top competitors include: Beam Therapeutics , Edgewise Therapeutics , Regulus Therapeutics
Answer: Dianthus Therapeutics contact info: Phone number: Website: https://dianthustx.com
Answer: Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Dianthus Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month